Episode 101
š§¬ Barry Ticho - Part 4 | Founding Verve Therapeutics Over Breakfast | Gene Editing for Cardiovascular Disease | Leadership Lessons From a First-Time Founder | Stokeās Vision for RNA-Based Medicines
Part 4 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas. Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.
The Biotech Startups Podcast Ā· Excedr
December 5, 202439m 40s
Audio is streamed directly from the publisher (media.fame.so) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The Biotech Startups Podcast, brought to you by Excedrāempowering life science startups with founder-friendly equipment leasing to fast-track R&D and drive commercialization success.
Know someone in need of lab equipment? Join Excedrās referral program: Give your friends $1,000 and earn $1,000 for every qualified referral! šø
Get your unique referral link here: refer.excedr.com/ZTHETY.
Part 4 of 4: Jon Chee hosts Barry Ticho, Founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, a biotech company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
With an MD PhD from the University of Chicago and extensive experience across academia and industry, Barry brings over two decades of expertise in clinical development. His journey includes roles as Head of Development at Moderna, Head of External R&D Innovation at Pfizer, and VP of Clinical Development at Biogen, where he's been instrumental in advancing numerous therapeutic programs across multiple disease areas.
Barry's unique perspective spanning academic medicine and biotechnology innovation makes his insights invaluable for aspiring leaders in the field.
Join us this week to hear about:
- Founding Verve Therapeutics and pioneering gene editing for cardiovascular disease
- Tackling medicine adherence with one-and-done gene therapies
- Leadership lessons from starting and scaling biotech startups
- How patient stories inspire innovation in genetic medicine
- Stokeās vision for genetic medicine and transformative treatments for diseases like Dravet syndrome
Please enjoy Jonās conversation with Barry Ticho.
Subscribe to the podcast: https://podcasts.apple.com/us/podcast/the-biotech-startups-podcast/id1679591994
Find Our Guest, Barry Ticho, at these links:
Find Our Host, Jon Chee, at these links:
Excedr Socials & Website
LinkedIn: https://www.linkedin.com/company/excedr/
Youtube: https://www.youtube.com/@excedr
Instagram: https://www.instagram.com/excedr_inc
Twitter: https://twitter.com/ExcedrInc
Facebook: https://www.facebook.com/excedr
TikTok: https://www.tiktok.com/@excedr
Podcast Website: https://www.thebiotechstartupspodcast.com/
Enriched Notes:
Topics Mentioned:
Verve Therapeutics: https://www.vervetx.com/
Stoke Therapeutics: https://www.stoketherapeutics.com/
Google Ventures: https://www.gv.com/
Mass General Hospital: https://www.massgeneral.org/
Brigham and Womenās Hospital: https://www.brighamandwomens.org/
Biogen: https://www.biogen.com/
University of Pennsylvania: https://www.upenn.edu/
Gene Editing and Its Impact on Cardiovascular Disease: https://www.health.harvard.edu/heart-health/gene-therapy-for-cardiovascular-disease
RNA-Based Medicines for Rare Disease Treatment: https://www.nature.com/articles/s41419-022-05075-2
Biotech Partnerships With Big Pharma: https://www.excedr.com/blog/how-biotech-partnerships-support-research
Business Development in Biotech: https://www.excedr.com/resources/business-development-in-the-life-sciences
Biotech Funding Options: https://www.excedr.com/resources/biotech-startup-funding-options
Scaling Biotechs to Meet Key Milestones with Leasing: https://www.excedr.com/blog/how-leasing-helps-biotechs-scale-efficiently
People Mentioned:
Sekar Kathiresan: https://www.linkedin.com/in/sekar-sek-kathiresan-3501846/
Timestamps:
00:00 Intro
02:15 Founding Verve Therapeutics over breakfast
05:31 Gene editing for cardiovascular disease: The PCSK9 story
07:49 Barryās experience as a first-time CEO
12:01 Joining Stoke Therapeutics and exploring RNA-based medicines
16:56 Building strong networks and the value of professional connections
22:09 Transitioning Stoke from private to public company
26:29 Hiring wisely and making difficult decisions quickly
30:09 Chief medical officer lessons: patient focus and team amplification
33:25 Stokeās future: Dravet syndrome trials and pipeline expansion
35:12 Shouts and advice to younger self
37:23 Outro
The Biotech Startups Podcast gives you a front-row seat to the business and science of building a biotech. Hosted by Jon Chee, CEO of Excedr, the show features honest conversations with founders, execs, and investors about their work, their companies, and how they got there. From scientific breakthroughs to startup lessons, each episode explores what it really takes to grow a life science companyāfrom pre-seed to IPO.